MPI Launches MammaPrint for Breast Cancer Patients

The Molecular Profiling Institute (MPI) announced that it is now providing the MammaPrint breast cancer test to breast cancer patients in the U.S. This is the first commercially available microarray cancer diagnostic that analyzes patients' breast tumors for their individual DNA expression profile.

EurekAlert (http://www.eurekalert.org/pub_releases/2005-04/ttgr-tmp042105.php)